JANX Janux Therapeutics, Inc.

NASDAQ
$17.63

Janux Therapeutics, Inc. (JANX) is expected to report earnings on February 4, 2027, after the market close. The consensus earnings estimate is a loss of $0.52 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +5.1% since its last earnings release on November 5, 2026.

Janux Therapeutics, Inc. Beat Consensus Estimates
Thursday, November 5, 2026 · 4:02 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 4
Thursday · 4:00 PM ET
Earnings Whisper
-
vs ($0.52)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $17.56

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Janux Therapeutics, Inc.

Janux is a clinical-stage biopharmaceutical company developing next-generation bispecific immunotherapies with the goal of fighting cancers by killing tumor cells while allowing healthy tissues to remain unharmed.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.